| Literature DB >> 34741480 |
Mojdeh Barati1, Behrad Darvishi2, Mohammad Amin Javidi1, Ali Mohammadian3, Seyed Peyman Shariatpanahi4, Mohammad Reza Eisavand2, Alireza Madjid Ansari1.
Abstract
Impaired apoptosis is one of the hallmarks of cancer, and almost all of the non-surgical approaches of eradicating tumour cells somehow promote induction of apoptosis. Indeed, numerous studies have stated that non-ionizing non-thermal extremely low-frequency magnetic fields (ELF-MF) can modulate the induction of apoptosis in exposed cells; however, much controversy exists in observations. When cells are exposed to ELF-EMF alone, very low or no statistically significant changes in apoptosis are observed. Contrarily, exposure to ELF-EMF in the presence of a co-stressor, including a chemotherapeutic agent or ionizing radiation, can either potentiate or inhibit apoptotic effects of the co-stressor. In our idea, the main point neglected in interpreting these discrepancies is "the cellular stress responses" of cells following ELF-EMF exposure and its interplay with apoptosis. The main purpose of the current review was to outline the triangle of ELF-EMF, the cellular stress response of cells and apoptosis and to interpret and unify discrepancies in results based on it. Therefore, initially, we will describe studies performed on identifying the effect of ELF-EMF on induction/inhibition of apoptosis and enumerate proposed pathways through which ELF-EMF exposure may affect apoptosis; then, we will explain cellular stress response and cues for its induction in response to ELF-EMF exposure; and finally, we will explain why such controversies have been observed by different investigators.Entities:
Keywords: ELF-EMF; apoptosis; cellular stress response; controversy; reactive oxygen species
Mesh:
Year: 2021 PMID: 34741480 PMCID: PMC8666288 DOI: 10.1111/cpr.13154
Source DB: PubMed Journal: Cell Prolif ISSN: 0960-7722 Impact factor: 6.831
Different cellular stress responses affected by ELF‐EMF exposure
| Experiment performed | ELF‐EMF treatment | Cell line | Observed effects |
|---|---|---|---|
| 1. Heat‐shock protein response | |||
| Corallo et al. | 100 Hz | Primary osteoarthritic chondrocytes | Increased Mn‐superoxide‐dismutase and heat‐shock proteins expression |
| Alfieri et al. | 50 Hz, 0.68 mT | Endothelial cells | A poor and transient activation of HSF1 |
| Frahm et al. | 50 Hz, 1 mT | Mouse macrophages | Hsp70 and Hsp110 exhibited increased levels at certain time point |
| Wei et al. | 15 Hz, 2 mT | Hypoxic cardiomyocytes | Significantly increased HSP70 mRNA expression |
| Bernardini | 50 Hz | Porcine aortic endothelial cells |
Increase in the mRNA levels of HSP70 No increase in Hsp27, Hsp70 and Hsp90 protein levels |
| Akan et al. | 50 Hz, 1 mT | THP‐1 cells | Increased hsp70 levels in a time‐dependent manner |
| 2. Unfold protein response | |||
| Chen et al. | Picosecond pulsed electric fields | HeLa cells | Affected the phosphorylation levels of endoplasmic reticulum sensors and upregulated the expression of GRP78, GRP94 and CHOP |
| Keczan et al. | PEMF | HEK263T | No remarkable effect |
| HepG2 | No remarkable effect | ||
| HeLa | Increased BiP, Grp94 and CHOP expression | ||
| 3. Autophagy | |||
| Chen et al. | Pulsed electromagnetic fields (2 mT, 50 Hz) | Embryonic fibroblasts (MEF) | A significant increase in autophagic biomarkers including LC3‐II and formation of GFP‐LC3 puncta was observed |
| 4. NF‐kB activation | |||
| Kim et al. | RAW264.7 cells | Enhanced translocation of phosphorylated NF‐κB in to the nucleus and induction of inflammatory responses | |
| 5. SIRT3 activation | |||
| Falone et al. |
ELF‐EMF 1 mT, 50 Hz | SH‐SY5Y | Upregulation of the major sirtuins, increased signalling activity of the NRF2 |
FIGURE 1ROS‐mediated apoptosis signalling pathways: (1) Accumulation of ROS affects p53 protein which in turn inhibits Bcl‐2 and Bcl‐XL proteins function and promotes the activity of Bad, Bax, Bak, Puma and Noxa proteins. (2) ROS can induce phosphorylation of JNK. Phosphorylated JNK can activate transcription factors such as SMAD3 and ATF2. Phosphorylated JNK can also translocate to the nucleus and activate C‐Jun phosphorylation which in turn can activate transcription of several pro‐apoptotic factors. (3) Accumulation of ROS inhibits PI3K‐mediated activation of AKT. (4) Accumulated ROS promotes ER stress and expression of CHOP through activation of ATF‐4 which in turn can promote Bax activity and inhibit Bcl‐2. (5) All these pathways end in the release of cytochrome c which in turn can activate caspase 9 and caspase 3 and result in cleavage of PARP and induction of apoptosis
FIGURE 2ROS‐mediated cellular stress response: (1) mild accumulation of ROS inhibits NADPH oxidase activity. (2) Mild accumulation of ROS activates antioxidant defence system which involves activation of transcription factors including NF‐kB, Nrf‐1 and AP‐1 which in turn upregulates expression of thioredoxin reductase, glutathione peroxidase, SOD, etc., which can suppress further accumulation of ROS. (3) Mild accumulation of ROS activates ER stress through affecting IRE6, ATF6 and PERK. PERK in turn inhibits general protein synthesis and ATF4 and functional XBP‐1 promote chaperon transcription, UPR genes and ERAD genes which can protect cells against accumulated ROS. (4) Mild accumulation of ROS can directly induce autophagy through inhibition of mTORC. (5) Mild accumulation of ROS can upregulate expression of HSP70 which can affect protein folding, proteasome activation and induction of autophagy. (6) Mild accumulation of ROS can also activate JNK and after that c‐JUN which can in turn activate BECN1, Atg4 and MAP1LC3B genes expressions, most important proteins involved in autophagy. ROS can also inhibit PI3K pathway and modulate autophagy. Finally, mild accumulation of ROS can induce specific decrease in RNA stability and result in mitochondrial activity shut down
Consequence of different sequential ELF‐EMF/stressor exposure on induction of apoptosis
| Classification of studies | ELF‐EMF treatment | Cell line | Agent co‐used (co‐stressor) | Interaction | |
|---|---|---|---|---|---|
| ELF‐EMF exposure prior to co‐stressor | |||||
| Kaszuba‐Zwoinska et al. | Pulsed electromagnetic field | 50 Hz, 45 ± 5 mT, 4 h/stimulation, 3 times in 24 h | Monocytic cell line MonoMac6 | Minocycline puromycin, colchicine, cyclophosphamide, hydrogen peroxide | Diminished amount of apoptotic and necrotic cells; enhanced expression of gene belonging to pro‐apoptotic family of Bcl‐2 and AIF agent (antagonism) |
| Harland et al. | Environmental‐level magnetic fields |
60 Hz, 1.2 µT 6 days | MCF‐7 |
Tamoxifen Melatonin | Significantly block the growth inhibitory action (antagonism) |
| Palumbo et al. | ELF‐EMF | Intermittent 50 Hz, 1 mT; 1 h | Jurkat cells | Anti‐Fas | Significant decrease of anti‐Fas‐induced apoptosis (antagonism) |
| Mansourian et al. | Static (DC) magnetic fields | 93.25–159.4 µT; 10 min | Erythroleukaemia K562 | Electrochemotherapy | Can incur resistance of the cells in response to electric pulses (antagonist) |
| Falone et al. | ELF‐EMF |
75 Hz, 1 mT 5–10 days | SH‐SY5Y human neuroblastoma |
H2O2 Doxorubicin | Reduced vulnerability against both H2O2 and ROS‐generating doxorubicin (antagonism) |
| De Nicola et al. | ELF‐EMF | 100 mT,N/A; 4 h | U937 cells | Puromycin | Protect U937 from apoptosis (antagonist) |
| Osera et al. | Pulsed EMF |
75 Hz, 2 mT 40 min | SH‐SY5Y cell line | H2O2 | Protected SH‐SY5Y cell line (antagonist) |
| Falone et al. | ELF‐EMF | 75 Hz, 2 mT | SK‐N‐BE(2) neuroblastoma | H2O2 | Reduced vulnerability against H2O2 (antagonist) |
| Simultaneous exposure to ELF‐EMF and co‐stressor | |||||
| Marcantonio et al. | ELF‐EMF |
50 Hz, 1 mT 24–72 h | Neuroblastoma BE(2)C | All trans retinoic acid (ATRA) | Decreased cellular proliferation and increased proportion of G0/G1 phase cells (potentiation) |
| Kaszuba‐Zwoinska et al. | Pulsed EMF |
50 Hz, 45 ± 5 mT 12 h | Neuroblastoma (U937) |
Puromycin Cyclophosphamide H2O2 Colchicine | PEMF protects U937 cells against puromycin‐induced cell death (antagonism) |
| Baharara et al. | ELF‐EMF |
50 Hz, 20 mT 2 h | A2780 ovarian cancer cells | Cisplatin | Increased apoptotic as well as necrotic cells (potentiation) |
| Ding et al. | ELF‐EMF |
60 Hz, 5 mT 24 h | Leukaemia HL‐60 | H2O2 | Changes generated by the ELF‐EMF can make resistant cells sensitive (potentiation) |
| Liburdy et al. | DC Fields | 12–50 Hz, 6.5 mT | MCF‐7 | Melatonin | Increased the number of apoptotic and necrotic cells (potentiation) |
| Cid et al. | ELF‐EMF |
50 Hz, 10 µT 90 h | HepG2 | Melatonin | Enhancement of proliferation by blocking melatonin's oncostatic action (antagonism) |
| Pirozzoli et al. | ELF‐EMF |
50 Hz, 1 mT 3 days | Neuroblastoma cell line LAN‐5 | Camptothecin | Enhancement of proliferation by blocking melatonin's oncostatic action (antagonism) |
| Brisdelli et al. | ELF‐EMF |
50 Hz, 1 mT 72 h | K562 cells | Quercetin | Protective effect towards apoptosis only at 24 h exposure (antagonism) |
| ELF‐EMF exposure following co‐stressor | |||||
| Jian et al. | Intermittent |
100 Hz, 0.7 mT 1–3 h | BEL‐7402 | X‐ray radiotherapy | Significantly higher apoptosis rates (potentiation) |
| Ruiz‐Gomez et al. | Pulsed EMF | 1–25 Hz, 1.5 mT; 1 h | Human colon adenocarcinoma (HCA) |
Vincristine Mitomycin Cisplatin | Increased cytotoxicity (potentiation) |
FIGURE 3A schematic illustration of the hypothesis for explanation of controversial effects of ELF‐EMF on apoptosis. Upper side: ELF‐EMF exposure prior to treatment with the apoptosis‐inducing agent will result in activation of cellular defence system and alteration in expression of a number of genes which, in next place, will end in promotion of DNA repair system, ROS detoxification system and Ca2+ homeostasis through production of new protective proteins and antioxidative enzymes or restoration of antioxidative stress molecule reservoirs such as glutathione and so on. In next place, upon introduction of the apoptosis‐inducing agent, cells will defend themselves with robust protective system and consequently, lower rate of apoptosis will occur. Lower side: Contrarily, ELF‐EMF co‐treatment with or immediately after chemotherapeutic agent will enhance the rate of injury by ROS overproduction or unbalancing Ca2+ homeostasis which will end in promotion of apoptosis